X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The trial will enroll up to 60 participants in one of two XT-150, a locally-injectable plasmid DNA gene therapy expressing IL-10v, dose groups or placebo for the treatment of facet joint osteoarthritis pain.
Lead Product(s): XT-150
Therapeutic Area: Immunology Product Name: XT-150
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2022
Details:
Fast Track designation is supportive of the clinical significance of our lead candidate, XT-150 that leverages plasmid DNA encoding the anti-inflammatory cytokine IL-10v for the treatment of pain associated with osteoarthritis of the knee.
Lead Product(s): XT-150
Therapeutic Area: Musculoskeletal Product Name: XT-150
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 17, 2021
Details:
The financing positioned Xalud’s to continue advancing lead therapeutic candidate, XT-150, a locally injectable plasmid DNA gene therapy expressing IL-10v – a proprietary long-acting, through clinical development and further expand our platform
Lead Product(s): XT-150
Therapeutic Area: Musculoskeletal Product Name: XT-150
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: PBM Capital
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing August 24, 2021
Details:
The primary efficacy evaluation of two potential therapeutic doses of XT-150 (150 and 450 μg) will be assessed at six months, followed by an additional six-month safety follow-up with the opportunity for a second injection. Topline results are expected in 4th quarter of 2021.
Lead Product(s): XT-150
Therapeutic Area: Musculoskeletal Product Name: XT-150
Highest Development Status: Phase II/ Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 20, 2021
Details:
XT-150 is currently in a Phase II/III trial for osteoarthritis, and Nguyen expects to read out topline Phase IIb data in Q4. XT-150, is a locally injectable plasmid DNA gene therapy expressing Interleukin 10 (IL-10).
Lead Product(s): XT-150
Therapeutic Area: Musculoskeletal Product Name: XT-150
Highest Development Status: Phase II/ Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
